Report      Database

    Cardiac Marker Analyzer Product Analysis, Business & Marketing Strategy of Cardiac Marker Companies - 2nd Edition

    Date: 18 Jul, 2017              Type: Medical Devices              Pages: 105

    Cardiac Marker Analyzer Product Analysis, Business & Marketing Strategy of Cardiac Marker Companies - 2nd Edition
    • Electronic Access - Single User License
      $1,500.00
    • CD-ROM Mail Delivery
      $1,600.00
    • Hard-copy Mail Delivery
      $1,600.00
    • Electronic Access - Multi User License
      $2,300.00

    Get 10% Free Customization in this Report

    Cardiac Marker Analyzer – Product Analysis

    Cardiometabolic products and services provide timely cardiovascular and metabolic information at the point-of-care. Until today, Troponin and CK-MB were the lead cardiac markers. Brain Natriuetic Pepetide (BNP) was recently introduced to differentiate between a Myocardial Infarction and Heart Failure. The routine markers of myocardial infarction – CK-MB, Troponin and Myoglobin and recently BNP are used in the acute care and tests such as Cholesterol are used to evaluate risk. A number of companies are focused on developing new cardiac markers.

    Alere delivers reliable and actionable health information through rapid diagnostic tests, resulting in better clinical and economic healthcare outcomes globally. Alere’s Cardiology net product sale was more than US$ 600 Million in 2016 and is expected to rule this industry in the future.

    Beckman Coulter offers the maximum number of cardiac marker tests on its cardiology platform while Abbott Laboratories (i-Stat) and Siemens Healthineers (Stratus® CS Analyzer) also perform several cardiac marker tests on their cardio-metabolism platform and establishes them as the leader in this market.

    Cardiac Markers Analyzers usually measure the levels of enzymes and proteins released from heart muscle when it is damaged.  Physicians use cardiac markers in two ways – to diagnose a cardiac event in a hospital emergency room or within the hospital or to evaluate a risk of a cardiovascular event occurring. 

    Cardiac Marker Analyzer – Product Analysis, Business & Marketing Strategy of Cardiac Marker Companies is the 2nd report published by Renub Research. This 105 page report contains 14 Figures and 12 Tables provides a comprehensive analysis of the cardiac markers analyzer segments, including their comparative tests analysis, competitive product analysis, product features, merger, acquisitions, analyzer sales figures and Business and Market Strategies of Companies.


    All the 12 Cardiac Marker Analyzers in the report have been studied from 5 viewpoints.
     
    1.    Analyzer Specifications and Benefits 
    2.    Net Product Sales
    3.    Merger, Acquisition & Licensing Agreement
    4.    Marketing Strategies
    5.    Methods of Distribution 


    The 12 Cardiac Marker Analyzer studied in the report are as follows:
     
    1.    Alere Meterpro Analyzer
    2.    RAMP 200
    3.    RAMP Reader
    4.    The i–STAT System
    5.    Cobas h 232 POC System
    6.    Stratus CS Analyzer
    7.    Access 2 Immunoassay System
    8.    ichroma DUO Analyzer
    9.    DXpress Reader Analyzer
    10.    PATHFAST Analyzer
    11.    Meritas POC Analyzer
    12.    QL Care Analyzer

     

    1.    Executive Summary

    2.    Cardiac Marker Companies – Comparative Tests Analysis

    3.    Cardiac Marker Analyzer – Competitive Product Analysis

    4.    Alere
    4.1    Alere Triage
    4.1.1    Triage MeterPro Analyzer

    4.2    Alere Cardiology Net Sales & Forecast (2011 - 2022) 

    5.    Response Biomedical
    5.1    Cardiovascular Testing
    5.1.1    Acute Myocardial Infarction (Heart Attack) Testing
    5.1.2    Congestive Heart Failure (“CHF”) Testing
    5.1.3    Thrombotic Disease Testing

    5.2    RAMP Platform
    5.2.1    RAMP 200
    5.2.2    RAMP Reader

    5.3    Response Biomedical Cardiovascular Net Sales (2011 – 2022) 

    6.    Abbott Point of Care
    6.1    The i–STAT System

    6.2    Abbott Laboratories Point of Care Diagnostics Sales (2011 – 2022) 

    7.    Roche
    7.1    Cobas h 232 POC System

    8.    Siemens Healthineers
    8.1    Stratus CS Analyzer

    8.2    Siemens Healthineers establishes global Digital Ecosystem to drive Digitalization of Healthcare

    9.    Beckman Coulter
    9.1    Access 2 Immunoassay System

    10.    Boditech
    10.1    i–chroma DUO Analyzer

    11.    Lifesign
    11.1    DXpress Reader Analyzer

    12.    LSI Medience Corporation
    12.1    PATHFAST Analyzer

    13.    Trinity Biotech
    13.1    Meritas POC Analyzer

    13.2    Trinity Biotech Point of Care Diagnostics Sales (2011 – 2022) 

    14.    CardioGenics Holdings Inc.
    14.1    QL Care Analyzer

    15.    Mergers, Acquisitions and Licensing Agreements
    15.1    Alere Inc

    15.2    Response Biomedical

    15.3    Abbott Laboratories

    15.4    Siemens Healthineers

    15.5    LSI Medience Corporation

    15.6    Trinity Biotech

    15.7    CardioGenics

    16.    Emerging Markers

    17.    Response Biomedical – Business & Marketing Strategy
    17.1    Reducing Research & Development (R&D) and Sales & Marketing Expenses under the Cost Reduction Strategy

    17.2    New Distributors in China

    17.3    Strategic Alliances with Alere Medical in Japan

    17.4    Response Biomedical Receives Health Canada Approval and CE Mark

    18.    Roche – Business & Marketing Strategy
    18.1    Implementing the Fully Connected Core Laboratory

    18.2    Expansion of Rich Test Menu

    18.3    Broadening the Diagnostics Portfolio

    18.4    Patient Safety Comes First

    19.    Siemens Healthineers – Business and Marketing Strategy
    19.1    Siemens Healthineers Announces New Strategic Relationship

    19.2    Cloud-Based Network Teamplay from Siemens Healthineers

    19.3    Strategic Partnership between Siemens and Imricor

    19.4    Siemens Healthineers Offers True High-Sensitivity Troponin I IVD Assay

    19.5    Siemens Healthineers & Digitalization

    19.6    Partnership between Siemens Healthineers and Ebit

    20.    Boditech Med Inc – Business and Marketing Strategy
    20.1    Boditech Med Acquires Immunostics

    20.2    Strong Focus on Manpower and Investments in Research & Development Area

    20.3    Advanced Technology in the Diagnostics Market

    20.4    Marketing Channel
     

    List of Figures

    Figure 4 1: Worldwide – Alere Cardiology Net Sales (Million US$), 2011 – 2016
    Figure 4 2: Worldwide – Forecast for Alere Cardiology Net Sales (Million US$), 2017 – 2022

    Figure 5 1: Worldwide – Response Biomedical Cardiovascular Product Sales (Million US$), 2011 – 2016
    Figure 5 2: Worldwide – Forecast for Response Biomedical Cardiovascular Product Sales (Million US$), 2017– 2022

    Figure 6 1: Worldwide – Abbott Laboratories Point of Care Diagnostics Sales (Million US$), 2011 – 2016
    Figure 6 2: Worldwide – Forecast for Abbott Laboratories Point of Care Diagnostics Sales (Million US$), 2017 – 2022

    Figure 7 1: WIFI Set-up
    Figure 7 2: QR CODE VIA BARCODE SCANNER Set-up
    Figure 7 3: QR CODE VIA SMART PHONE APP Set-up
    Figure 7 4: Connectivity of cobas h 232 in pre-hospital care and within hospital Set-up

    Figure 13 1: Worldwide – Trinity Biotech Point of Care Diagnostics Sales (Million US$), 2011 – 2016
    Figure 13 2: Worldwide – Forecast for Trinity Biotech Point of Care Diagnostics Sales (Million US$), 2017 – 2022

    Figure 20 1: Boditech – R&D Manpower, Jan 2016
    Figure 20 2: Boditech – R&D Investments (Million US$), Jan 2016
        

    List of Tables    

    Table 2 1: Cardiac Marker Companies – Comparative Tests Analysis
    Table 2 2: Cardiac Marker Companies – Comparative Tests Analysis
    Table 2 3: Cardiac Marker Companies – Comparative Tests Analysis

    Table 3 1: Cardiac Marker Analyzer – Competitive Product Analysis
    Table 3 2: Cardiac Marker Analyzer – Competitive Product Analysis

    Table 6 1: i-STAT 1 Analyzer Specification

    Table 12 1: PATHFAST – Technical Specifications

    Table 15 1: Mergers, Acquisitions and Licensing Agreements, 2003 - 2017

    Table 18 1: Roche - Centralised and Point of Care Solutions Product Launches, 2017
    Table 18 2: Roche - Molecular Diagnostics Product Launches, 2017
    Table 18 3: Roche - Tissue Diagnostics Product Launches, 2017
    Table 18 4: Roche - Sequencing Product Launches, 2017


    Related Products

    • High Intensity Focused Ultrasound (HIFU) Product Analysis of 20 Manufacturers & Deals


      High Intensity Focused Ultrasound (HIFU) Product Analysis of 20 Manufacturers & Deals
      High-Intensity Focused Ultrasound (HIFU) is an FDA-approved, minimally invasive therapeutic technology with the potential to transform the treatment of many medical disorders by using ultrasonic energy to target tissue. Till date more than 100,000 patients have been treated with HIFU therapeutic tec...
      Date: 18 May, 2017
      Type: Medical Devices
      Pages: 150
      Price: $1,150.00
    • Blood Coagulation Analyzer - Product Analysis


      Blood Coagulation Analyzer - Product Analysis
      This 125 page report "Blood Coagulation Analyzer - Product Analysis" contains 4 figures and 40 Tables provides a comprehensive assessment of the blood coagulation products of the companies. It examines the latest available and emerging coagulation tests and products being utilized by the coagulation...
      Date: 22 Jan, 2015
      Type: Life Science
      Pages: 125
      Price: $900.00
    • Cardiac Marker Analyzer - Worldwide Analysis


      Cardiac Marker Analyzer - Worldwide Analysis
      Point of Care Testing (POCT) enables rapid diagnostic tests to be performed while the patient is at the point of care facility where results can be obtained immediately, rather than waiting hours or even days for outside lab results to arrive. Cardiac Marker analyzer represents a paradigm in diagnos...
      Date: 09 Sep, 2014
      Type: Life Science
      Pages: 62
      Price: $800.00